Corrigendum to "Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings" [Obes. Pillars, Volume 11, September 2024, 100112].

[This corrects the article DOI: 10.1016/j.obpill.

Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings.

Background: To evaluate the weight loss outcomes of the large US cohort of patients undergoing endoscopic sleeve gastroplasty (ESG) with or without concomitant anti-obesity (AOM) use.

Methods: We performed a retrospective analysis of adult patients who underwent ESG from seven different sites, from January 1, 2020 to November 30, 2022. Percent total body weight loss (%TBWL) and %excess weight loss (%EWL) were calculated based on baseline weight at the procedure.

Practice patterns and outcomes of endoscopic sleeve gastroplasty based on provider specialty.

Endoscopic sleeve gastroplasty (ESG) is performed in clinical practice by gastroenterologists and bariatric surgeons. Given the increasing regulatory approval and global adoption, we aimed to evaluate real-world outcomes in multidisciplinary practices involving bariatric surgeons and gastroenterologists across the United States. We included adult patients with obesity who underwent ESG from January 2013 to August 2022 in seven academic and private centers in the United States.

Performance of Endoscopic Sleeve Gastroplasty by Obesity Class in the United States Clinical Setting.

Introduction: Endoscopic sleeve gastroplasty (ESG) has gained popularity over the past decade and has been adopted in both academic and private institutions globally. We present outcomes of the largest cohort of patients from the United States undergoing ESG and evaluate these according to obesity class.

Methods: We performed a retrospective analysis of adult patients who underwent ESG.

Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.

Objective: This study determined the optimal timing of insulin bolus administration in relation to meal consumption in adolescents and adults with type 1 diabetes.

Study Design And Methods: Twenty-three subjects participated in this crossover study consisting of three treatment arms: delivering an insulin glulisine bolus by insulin pump 20 min prior to a meal ("PRE"), immediately before the meal ("START"), and 20 min after meal initiation ("POST"). Blood glucose levels were measured every 30 min for a total of 240 min post-meal initiation.

Missed insulin boluses for snacks in youth with type 1 diabetes.

OBJECTIVE To evaluate the effects of missed insulin boluses for snacks in youth with type 1 diabetes. RESEARCH DESIGN AND METHODS Three months of simultaneous continuous subcutaneous insulin infusion and continuous glucose monitoring data from nine subjects were retrospectively evaluated. Glucose excursions between 1330 and 1700 h were defined as relating to snacks with insulin or snacks with no insulin administered.

Continuous glucose monitoring in youth with type 1 diabetes.

Continuous glucose monitoring (CGM) is becoming increasingly popular and represents the third era of diabetes management. Currently available CGM devices have been studied in youth with type 1 diabetes and show similar accuracy across all age groups. Tolerability of these devices relates to alarm settings, sensor skin irritation, and durability of the device.